Allogeneic stem cell transplantation after reduced-intensity conditioning in patients with myelofibrosis: A prospective, multicenter study of the Chronic LeukemiaWorking Party of the European Group for Blood and Marrow Transplantation

Blood

Volumn 114, Issue 26, 2009, Pages 5264-5270

  Kröger, Nicolaus ^a   Holler, Ernst ^b   Kobbe, Guido ^c   Bornhäuser, Martin ^d   Schwerdtfeger, Rainer ^e   Baurmann, Herrad ^f   Nagler, Arnon ^f   Bethge, Wolfgang ^g   Stelljes, Matthias ^h   Uharek, Lutz ⁱ   Wandt, Hannes ^j   Burchert, Andreas ^k   Corradini, Paolo ^l   Schubert, Jörg ^m   Kaufmann, Martin ⁿ   Dreger, Peter ^o   Wulf, Gerald G ^p   Einsele, Hermann ^q   Zabelina, Tatjana ^a   Kvasnicka, Hans Michael ^r   Thiele, Jürgen ^r   Brand, Ronald ^s   Zander, Axel R ^a   Niederwieser, Dietger ^t   De Witte, Theo M ^u   more..

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b UNIVERSITY HOSPITAL REGENSBURG   (Germany)

^c UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

^d UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^e DKD   (Germany)

^f SHEBA MEDICAL CENTER   (Israel)

^g UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^h UNIVERSITY HOSPITAL MÜNSTER   (Germany)

ⁱ CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^j KLINIKUM NÜRNBERG   (Germany)

^k UNIVERSITY HOSPITAL MARBURG   (Germany)

^l NATIONAL CANCER INSTITUTE   (Italy)

^m SAARLAND UNIVERSITY   (Germany)

ⁿ ROBERT BOSCH GMBH   (Germany)

^o UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^p UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

^q UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^r UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^s LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^t UNIVERSITY HOSPITAL LEIPZIG   (Germany)

^u RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BUSULFAN; FLUDARABINE; JANUS KINASE 2; LEUKOCYTE ANTIGEN; DRUG DERIVATIVE; MYELOABLATIVE AGENT; VIDARABINE;

ACUTE GRAFT VERSUS HOST DISEASE; ADULT; AGED; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; CHRONIC GRAFT VERSUS HOST DISEASE; CHRONIC LEUKEMIA; CLINICAL TRIAL; CONTROLLED STUDY; EUROPE; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LEUKOCYTE TRANSFUSION; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTICENTER STUDY; MYELOFIBROSIS; MYELOID METAPLASIA; PHASE 2 CLINICAL TRIAL; POLYCYTHEMIA VERA; PRIORITY JOURNAL; RELAPSE; SURVIVAL RATE; THROMBOCYTE TRANSFUSION; THROMBOCYTHEMIA; TREATMENT RESPONSE; ALLOTRANSPLANTATION; DISEASE FREE SURVIVAL; GRAFT VERSUS HOST REACTION; IMMUNOSUPPRESSIVE TREATMENT; METHODOLOGY; MIDDLE AGED; RECURRENT DISEASE; STEM CELL TRANSPLANTATION;

ADULT; AGED; BUSULFAN; DISEASE-FREE SURVIVAL; FEMALE; GRAFT VS HOST DISEASE; HUMANS; MALE; MIDDLE AGED; MYELOABLATIVE AGONISTS; PRIMARY MYELOFIBROSIS; RECURRENCE; STEM CELL TRANSPLANTATION; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; VIDARABINE;

EID: 73949084969     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2009-07-234880     Document Type: Article

References (23)

1. Mesa RA, Verstovsek S, Cervantes F, et al. Primary myelofibrosis (PMF), post polycythemia vera myelofibrosis (post-PV MF), post essential thrombocythemia myelofibrosis (post-ET MF), blast phase PMF (PMF-BP): consensus on terminology by the international working group for myelofibrosis research and treatment (IWG-MRT). Leuk Res. 2007;31(6):737-740.
2. Barosi G, Hoffman R. Idiopathic myelofibrosis. Semin Hematol. 2005;42(4):248-258.
3. Mesa RA, Silverstein MN, Jacobsen SJ, Wollan PC, Tefferi A. Population-based incidence and survival figures in essential thrombocythemia and agnogenic myeloid metaplasia: an Olmsted County Study, 1976-1995. Am J Hematol. 1999;61(1):10-15.
4. Guardiola P, Anderson JE, Bandini G, et al. Allogeneic stem cell transplantation for agnogenic myeloid metaplasia: a European Group for Blood and Marrow Transplantation, Societe Francaise de Greffe de Moelle, Gruppo Italiano per il Trapianto del Midollo Osseo, and Fred Hutchinson Cancer Research Center Collaborative Study. Blood. 1999;93(9):2831-2838.
5. Kerbauy DM, Gooley TA, Sale GE, et al. Hematopoietic cell transplantation as curative therapy for idiopathic myelofibrosis, advanced polycythemia vera, and essential thrombocythemia. Biol Blood Marrow Transplant. 2007;13(3):355-365.
6. Guardiola P, Anderson JE, Gluckman E. Myelofibrosis with myeloid metaplasia [letter]. N Engl J Med. 2000;343(9):659.
7. Rondelli D, Barosi G, Bacigalupo A, et al. Myeloproliferative Diseases-Research Consortium. Allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning in intermediate- or high-risk patients with myelofibrosis with myeloid metaplasia. Blood. 2005;105(10):4115-4119.
8. Kröger N, Zabelina T, Schieder H, et al. Pilot study of reduced-intensity conditioning followed by allogeneic stem cell transplantation from related and unrelated donors in patients with myelofibrosis. Br J Haematol. 2005;128(5):690-697.
9. Kröger N, Thiele J, Kobbe G, et al. Rapid regression of bone marrow fibrosis after dose-reduced allogeneic stem cell transplantation. Exp Hematol. 2007;35(11):1719-1722.
10. Byrne JL, Beshti H, Clark D, et al. Induction of remission after donor leucocyte infusion for the treatment of relapsed chronic idiopathic myelofibrosis following allogeneic transplantation: evidence for a 'graft vs myelofibrosis' effect. Br J Haematol. 2000;108(2):430-433.
11. Cervantes F, Rovira M, Urbano-Ispizua A, Rozman M, Carreras E, Montserrat E. Complete remission of idiopathic myelofibrosis following donor lymphocyte infusion after failure of allogeneic transplantation: demonstration of a graft-versus-myelofibrosis effect. Bone Marrow Transplant. 2000;26(6):697-699.
12. Kröger N, Alchalby H, Klyuchnikov E, et al. JAK2-V617F-triggered preemptive and salvage adoptive immunotherapy with donor-lymphocyte infusion in patients with myelofibrosis after allogeneic stem cell transplantation. Blood. 2009;113(8):1866-1868.
13. Benjamini O, Koren-Michowitz M, Mariglio N, Kroger N, Nagler A, Shimoni A. Relapse of post-polycythemia myelofibrosis after allogeneic stem cell transplantation in a polycythemic phase: successful treatment with donor lymphocyte infusion directed by quantitative PCR test for V617F-JAK2 mutation. Leukemia. 2008;22(10):1961-1963.
14. Dupriez B, Morel P, Demory JL, et al. Prognostic factors in agnogenic myeloid metaplasia: a report on 195 cases with a new scoring system. Blood. 1996;88:1013-1018.
15. Cervantes F, Barosi G, Demory JL, et al. Myelofibrosis with myeloid metaplasia in young individuals: disease characteristics, prognostic factors and identification of risk groups. Br J Haematol. 1998;102:684-690.
16. Glucksberg H, Storb R, Fefer A, et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HLA-matched sibling donors. Transplantation. 1974;18:295-304.
17. Shulman HM, Sullivan KM, Weiden PL, et al. Chronic graft-versus-host syndrome in man: a long-term clinicopathologic study of 20 Seattle patients. Am J Med. 1980;69(2):204-217.
18. Kröger N, Badbaran A, Holler E, et al. Monitoring of the JAK2-V617F mutation by highly sensitive quantitative real-time PCR after allogeneic stem cell transplantation in patients with myelofibrosis. Blood. 2007;109(3):1316- 1321.
19. Patriarca F, Bacigalupo A, Sperotto A, et al. Allogeneic hematopoietic stem cell transplantation in myelofibrosis: the 20 year experience of the Gruppo Italiano Trapianto di Midollo Osseo (GITMO). Haematologica. 2008;93(10):1514-1522.
20. Tefferi A, Mesa RA, Nagorney DM, Schroeder G, Silverstein MN. Splenectomy in myelofibrosis with myeloid metaplasia: a single-institution experience with 223 patients. Blood. 2000;95(7):2226-2233.
21. Kröger N, Mesa RA. Choosing between stem cell therapy and drugs in myelofibrosis. Leukemia. 2008;22(3):474-486.
22. Pardanini A. JAK2 inhibitor therapy in myeloproliferative disorders: rationale, preclinical studies and ongoing clinical trials. Leukemia. 2008;22(1):23-30.
23. Koren-Michowitz M, Shimoni A, Vivante A, et al. A new MALDI-TOF-based assay for monitoring JAK2 V617F mutation level in patients undergoing allogeneic stem cell transplantation (all SCT) for classic myeloproliferative disorders (MPD). Leuk Res. 2008;32(3):421-427.